Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18266
Country/Region: Haiti
Year: 2016
Main Partner: GHESKIO
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,600,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $221,030
Care: TB/HIV (HVTB) $72,000
Care: Pediatric Care and Support (PDCS) $190,232
Laboratory Infrastructure (HLAB) $100,000
Strategic Information (HVSI) $105,250
Health Systems Strengthening (OHSS) $90,000
Testing: HIV Testing and Counseling (HVCT) $163,514
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $108,120
Treatment: Adult Treatment (HTXS) $1,310,000
Treatment: Pediatric Treatment (PDTX) $239,854
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 289
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 31
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 289
GEND_GBV Number of people receiving post-GBV care 2017 320
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 3,210
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 3,210
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 46,579
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 33,730
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 86,729
HTS_TST Service Delivery Point (Facility): Inpatient 2017 867
HTS_TST Service Delivery Point (Facility): Pediatric 2017 6,420
HTS_TST Service Delivery Point (Facility): PMTCT 2017 4,611
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,827
HTS_TST Service Delivery Point (Facility): VCT 2017 73,004
HTS_TST Sum of Aggregated Age/Sex <15 2017 6,420
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 80,309
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 86,729
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 86
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 86
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 1,076
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 779
PMTCT_ART Already on ART at beginning of current pregnancy 2017 33
PMTCT_ART New on ART 2017 44
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 4,611
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 43
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 34
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 2
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 4
PMTCT_EID Sum of Infant Age disaggregates 2017 77
PMTCT_STAT By: Known positives at entry 2017 38
PMTCT_STAT By: Number of new positives identified 2017 43
PMTCT_STAT Number of new ANC and L&D clients 2017 4,652
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 4,611
PMTCT_STAT Sum of Positives Status disaggregates 2017 81
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 164
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 111
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 282
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 282
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 287
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 86
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 287
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 43
TB_SCREENDX Screen Result: Screened Positive for TB 2017 287
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 7,796
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 5,196
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 212
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 141
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 13,345
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 30
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,066
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 19
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 712
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,827
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 2,158
TX_CURR Aggregated Age/Sex: <15 Female 2017 212
TX_CURR Aggregated Age/Sex: <15 Male 2017 141
TX_CURR Aggregated Age/Sex: 15+ Female 2017 7,796
TX_CURR Aggregated Age/Sex: 15+ Male 2017 5,196
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 13,345
TX_CURR Sum of Aggregated Age/Sex <15 2017 353
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 12,992
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 13,345
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 38
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 38
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 1,352
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 976
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 2,404
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 2,404
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 13,345
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 10,009
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 159
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 106
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 5,847
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,897
TX_PVLS Numerator: Indication: Routine 2017 9,008
TX_PVLS Numerator: Indication: Targeted 2017 1,001
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 212
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 141
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 7,796
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 5,196
TX_PVLS_den Denominator: Indication: Routine 2017 12,010
TX_PVLS_den Denominator: Indication: Targeted 2017 1,335
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 62
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 41
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,235
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 720
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,058
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,390
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 71
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 48
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,434
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 837
Cross Cutting Budget Categories and Known Amounts Total: $2,075,000
Motor Vehicles: Purchased $60,000
Gender: Gender Based Violence (GBV) $150,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Human Resources for Health $1,800,000
Key Populations: Sex Workers $35,000
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG $30,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information